Japan’s health ministry approved a slew of new medicines on September 25 including multiple “first of its kind” products, among them being GlaxoSmithKline’s respiratory syncytial virus (RSV) vaccine Arexvy as well as Eisai’s Alzheimer’s therapy Leqembi (lecanemab).Arexvy became the first…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Astellas Pharma Debuts on DJSI Asia Pacific Index
September 28, 2011
-
BUSINESS BMS to File for Apixaban for Stroke Prevention in Japan, US, and Europe Before Year-end
September 27, 2011
-
ORGANIZATION Continuation of Premium for New Drug Development to Depend on Effects on Drug Lag, Drug Development: Mr Shirakawa of Kenporen
September 26, 2011
-
REGULATORY 6 APIs/10 Products Including EpiPen Added to NHI Price List
September 22, 2011
-
BUSINESS Novartis Grows 7% Driven by New Products: President Mitani
September 22, 2011
-
BUSINESS Kaken President Onuma Targets ¥20 Billion in Operating Profits in 2015
September 21, 2011
-
ORGANIZATION FPMAJ Seeks Improved System for Orphan Drug Development, Request to Be Submitted Soon to Health Minister
September 20, 2011
-
REGULATORY HSC Subcommittee Agrees on Need for New System to Promote Access to Unapproved Drugs
September 20, 2011
-
REGULATORY Preparations Underway for MHLW to Set Up Private Third-Party Committee
September 16, 2011
-
REGULATORY Council Recommends 5 Drugs as Appropriate for Application Based on Info. in Public Domain
September 16, 2011
-
BUSINESS Small, Medium-Sized Generic Drug Makers’ Business Improves Amid Uncertainty Over Future
September 15, 2011
-
BUSINESS Supreme Court Rules Against GE Drug Makers, Allows Patent Extension for Eisai’s Aricept
September 15, 2011
-
ACADEMIA NCGM Hospital Removes Actos from List of Recommended Drugs in Diabetes Manual
September 14, 2011
-
ORGANIZATION FPMAJ Announces Its Basic Policy on Providing Info. on Drugs Used Off-label
September 13, 2011
-
BUSINESS Takeda Initiates PIII Trials of Antidiabetic TAK-875 in Japan
September 13, 2011
-
BUSINESS NBI Initiates PIII Study for BIBF1122 in Japan
September 12, 2011
-
REGULATORY MHLW Director-General Kikura Indicates “Firm Resolve” for Structural Improvement to Eliminate Drug Disasters
September 12, 2011
-
ACADEMIA Clinical Positioning Needs to Be Clarified for Nexavar, Sutent: Prof. Naito of Kyushu Univ.
September 12, 2011
-
REGULATORY MHLW’s Council to Draw Up 10-Year Strategy for Hepatitis
September 9, 2011
-
REGULATORY Council Recommends Subsidization of Peginterferon Therapy for Chronic Active Hepatitis B
September 9, 2011
ページ
In the run-up to FY2024 budget requests this summer, there were growing hopes in the pharmaceutical industry that the government's de-facto cap on increases in social security spending would finally be lifted. That did not happen, despite strong calls from…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…